Credit Suisse analyst Kennen MacKay sees the March 14 presentation of full data from AstraZeneca's (AZN) SOLO2 trial of Lynparza in gBRCA+ 2L maintenance ovarian cancer at the Society of Gynecologic Oncology's annual meeting as a potential positive read through to Clovis' (CLVS) Phase 3 ARIEL3 trial of Rubraca in 2L+ maintenance. If AstraZeneca's SOLO2 mPFS and hazard ratio are competitive with those of TESARO's (TSRO) NOVA trial, the analyst sees data from the treatment setting suggestive that Clovis' Rubraca may achieve similar results. He reiterates an Outperform rating and $70 price target on Clovis' shares.